Navigation Links
Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
Date:8/8/2012

MALVERN, Pa., Aug. 8, 2012 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced that executive management will participate in the Canaccord Genuity 32nd Annual Growth Conference to be held August 14-16, 2012 at the InterContinental Hotel in Boston.  Mr. Adrian Adams, Chief Executive Officer and President, is scheduled to present an overview of the Company and its product pipeline at 2:00 p.m. ET on Wednesday, August 15, 2012.  

(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO)

The presentation will also be webcast on the "For Investors" section of the Auxilium website under the "Events" tab on August 15, 2012.  The presentation slides to be used will be available on the "For Investors" section of the Auxilium website under the "Presentations" tab on August 15, 2012. To access the live webcast, please log on to Auxilium's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.  The presentation replay will be available for ninety days after the event.About AuxiliumAuxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences. Auxilium markets Testim® 1% (testosterone gel) for the topical treatment of hypogonadism in the U.S. and XIAFLEX® (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord. GlaxoSmithKline LLC co-promotes Testim with Auxilium in the U.S.  Ferring International Center S.A. markets Testim in certain countries of the EU and Paladin Labs Inc. markets Testim in Canada.  Pfizer has marketing rights for XIAPEX® (the EU tradename for collagenase clostridium histolyticum) in 46
'/>"/>

SOURCE Auxilium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
2. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
3. Auxilium Announces Appointments to Enhance Leadership Team
4. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
5. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
8. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
9. Robert Kirsner, MD, PhD, To Present Results For Phase 2b 6-Month Follow-Up Trial Of Unique Investigational Cell-Based Therapy For Venous Leg Ulcers
10. Keryx Biopharmaceuticals to Present at The 7th Annual JMP Securities Healthcare Conference
11. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)...  Blueprint Medicines (NASDAQ: BPMC ) today ... of 9,367,708 shares of common stock at a ... shares of common stock issued upon the full ... purchase additional shares. The gross proceeds from the ... $168.6 million, before underwriting discounts and estimated offering expenses. ...
(Date:5/5/2015)... 2015 Hayden-McNeil is pleased ... custom course materials for smaller courses. This program is ... as 200 students. , “I’m very excited about ... higher education instructors,” said Jeff McCarthy, Hayden-McNeil president. “By ... do our part to make education both more effective ...
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, a ... heart failure and other chronic diseases, has engaged ... analysis designed to reflect the healthcare patterns of ... model will be used to characterize the impact ... have on those groups of patients and the ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Franz Inc ... technology, today announced that its flagship product, AllegroGraph, has been ... Graph Database Market Update report. AllegroGraph is a ... the W3C industry standards. Graph databases are skyrocketing in popularity ... according to a recent DBMS ranking by DB-Engines. ...
Breaking Biology Technology:Blueprint Medicines Announces Closing of Initial Public Offering 2Hayden-McNeil Expands Publishing Program to Service Lower Enrollment Courses 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 2Bloor Research Positions AllegroGraph as a ‘Champion’ in Burgeoning Graph Database Market 3
... populations with regard to risk associated in the development of ... osteoporosis or cardiovascular disease, - North American ... in response to nutritional products (nutrigenomics),- North ... Feb. 28 Interleukin Genetics,Inc. (Amex: ILI ) reported today ...
... the following Webcast:, What: Transgenomic Inc. Fourth ... Conference Call, When: Thursday, February 28, ... How: Live over the Internet -- Simply ... address above., To access the call via telephone, ...
... SAN DIEGO, Feb. 28 Anadys Pharmaceuticals,Inc. (Nasdaq: ... in a,Phase I study of ANA773, the company,s oral ... first-in-human trial is a safety,and tolerability study designed to ... as to select the dose and,schedule for Phase II ...
Cached Biology Technology:Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 2Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 3Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 4Interleukin Genetics Enters into New Clinical Research Collaboration with Alticor 5Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 2Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 3Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients 4
(Date:4/20/2015)... -- Huntington Memorial Hospital is the first facility in ... wireless monitoring sensor to manage heart failure (HF). The ... heart failure monitoring device that has been proven to ... manage heart failure. The CardioMEMS HF System ... artery (PA) during a non-surgical procedure to directly measure ...
(Date:4/14/2015)... , April 14, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... nominated for the 2015 New York Design Awards under ... Design100, New York City Design Awards are part of ... on over 2,500 ratings from the marketplace, industry and ...
(Date:4/9/2015)... , April 9, 2015 Synaptics Inc. (NASDAQ: ... solutions, announced today that it will report financial results ... April 23, 2015, after the close of market. The ... and investors at 2:00 p.m. PT (5:00 p.m. ET), ... To participate on the live call, analysts and ...
Breaking Biology News(10 mins):Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 2Huntington Memorial Hospital Becomes First in the San Gabriel Valley to Offer Patients a New Heart Failure Monitoring Solution 3NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3Synaptics to Report Third Quarter Results on April 23 2
... Biology, researchers report using DNA from tissues samples collected in 1955 ... ( Orcinus orca ). In 1955, a pod ... a skeleton was saved in a museum in Wellington. Photographs were ... form of killer whale, characterized by a very small white eye-patch ...
... A decade-long JDRF-funded study led by the Institute ... providing a deeper understanding of the link between autoantibodies ... highlighting the importance of pre-diabetes research into possible preventions ... Autoantibodies and Risk of Progression to Diabetes in Children," ...
... 19, 2013  New York College of Health Professions announces the ... Office for detecting biometric changes through smart phones, apps and ... or killed. This patent is part of an ... College of Health Professions. Lisa Pamintuan , ...
Cached Biology News:New data on islet autoantibodies in young children defines early type 1 diabetes development 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 2New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 3New Technology Using Biometrics Detects If Security Guards Are Attacked, Injured Or Killed 4
... He biolistic system enables 7-10 times more cells ... fits into the shocking chamber of the PDS-1000 ... wave over 7 microcarriers. By uniformly spreading the ... area, the system maximizes the number of cells ...
... BioLogic LP system, 220-240 V, is ... fraction collection. The system includes the ... kit with MV-6 injection valve, proportioning ... cell, tubing and fittings kit, column ...
Lyophilized solid. Suitable for evaluating functional activity of human complement components and for other research requiring a high level of hemolytic activity. ...
... VersArray ChipWriter Pro system with colony-picking capabilities, ... to array DNA, proteins, oligonucleotides, carbohydrates, lipids, ... substrates for microarray applications. This system can ... small as 300 micrometers in diameter and ...
Biology Products: